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Qing-Yun Wang,1 Tang-Chun Wu,3 Huan Guo,3 Hui Liu,1 Tao Guo,1 Jian-Ming Yu,1 Rui Yang,1
Yan Yang,1 and Yu Hu1,*
Venous thrombosis is a major medical disorder caused by both genetic and environmental factors. Little is known about the genetic
background of venous thrombosis in the Chinese population. A total of 1,304 individuals diagnosed with a first venous thrombosis
and 1,334 age- and sex-matched healthy participants were enrolled in this study. Resequencing of THBD (encoding thrombomodulin)
in 60 individuals with venous thrombosis and 60 controls and a functional assay showed that a common variant, c.151G>T
(rs16984852), in the 50 UTR significantly reduced the gene expression and could cause a predisposition to venous thrombosis. Therefore,
this variant was genotyped in a case-control study, and results indicated that heterozygotes had a 2.80-fold (95% confidence interval ¼
1.88–4.29) increased risk of venous thrombosis. The THBD c.151G>T variant was further investigated in a family analysis involving
176 first-degree relatives from 38 index families. First-degree relatives with this variant had a 3.42-fold increased risk of venous throm-
bosis, and their probability of remaining thrombosis-free was significantly lower than that of relatives without the variant. In addition,
five rare mutations that might be deleterious were also identified in thrombophilic individuals by sequencing. This study is the largest
genetic investigation of venous thrombosis in the Chinese population. Further study on genetics of thrombosis should focus on rese-
quencing of THBD and other hemostasis genes in different populations.Introduction
Venous thrombosis (VT) and its sequela, postthrombotic
syndrome, are major medical disorders throughout the
world. VT is a common disease that has a high morbidity
and mortality rate shortly after the event.1 The relevant
data have shown that the incidence is approximately 1–3
per 1,000 persons per year in Western countries.2 Early
epidemiological studies have suggested that the directly
standardized incidence of all VT events is significantly
higher among African Americans (138–141 cases per
100,000 individuals per year) than among Caucasians
(80–117 cases per 100,000 individuals per year), signifi-
cantly lower among Hispanic populations (55–61.5 cases
per 100,000 individuals per year), and strikingly lower
among Asians and Pacific Islanders (21–29 cases per
100,000 individuals per year).3,4 With the improvement
of its diagnosis and the development of access to health-
care, VT in Asian populations is now believed to be
common,5,6 and in particular, the absolute number is
thought to be great as a result of the large population.
Several genetic and environmental risk factors are involved
in the pathogenesis of this complex disease.7–11 Acquired
and environmental factors include advancing age, immo-
bilization, multiple trauma, major general surgery, preg-
nancy, superficial vein thrombosis, oral contraceptives,
hormone replacement, inflammation, and active
cancer.12–14 Ethnic differences are implicated in the in-
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The Americprotein C) response caused by the factor-V-Leiden muta-
tion in the coding sequence of F5 (MIM 612309),16–18
a common prothrombin-G20210A mutation in the 30
UTR of F2 (MIM 176930),19 and the antithrombin-Cam-
bridge-II mutation in SERPINC1 (MIM 107300)20 are
common genetic risk factors for VT in whites. However,
these polymorphisms are rare in Asians, including Chinese
populations. Little is known about the genetic background
of VT, and no common genetic risk factors have been iden-
tified in the Chinese population until recently.21–23
However, despite the discoveries described above, the
underlying molecular mechanisms of a considerable
number of inherited thrombotic events remain
unsolved.11 Mounting evidence indicates that genetic vari-
ation within the procoagulant, anticoagulant, and fibrino-
lytic pathways might be a potential risk factor for VT.24–28
Thrombomodulin (TM, encoded by THBD [MIM 188040]),
a critical component of the protein C pathway, is a glycosy-
lated type I transmembrane protein of 557 amino acids
and is expressed mainly on the endothelial surface of
blood vessels.29 The anticoagulant property of TM is medi-
ated by its interaction with thrombin (the activated form
of prothrombin) and protein C (PC, encoded by PROC
[MIM 612283]). The high-affinity binding of thrombin to
TM results in a greater than 1,000-fold amplification of
the rate of thrombin-dependent PC activation. Thus,
APC (the activated form of PC) inhibits the coagulation
pathway by proteolysis of coagulation factor Va (the acti-
vated form of coagulation factor V) and coagulation factorg University of Science and Technology, Wuhan, Hubei 430022, China;
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VIIIa (the activated form of coagulation factor VIII,
encoded by F8 [MIM 300841]).30 Akin to the cofactor
function in anticoagulation, TM is also reported to be asso-
ciated with fibrinolysis, embryonic development, arterio-
sclerosis, inflammation regulation, and tumor growth
and metastasis.31–35
On the basis of the crucial antithrombotic role of TM, we
investigated THBD as a candidate gene and report
a common mutation for VT in the Chinese population in
the present study. Then, we analyzed all these common
genetic risk factors identified in the Chinese population,
and the results might explain why ethnicity affects the
incidence of VT.36Subjects and Methods
Study Population
Some of the current study population was based on the cohort
from the previous case-control study (1,003 VT individuals and
1,031 controls).21 To obtain fresh plasma samples and introduce
more known risk factors for thrombosis, we recruited some partic-
ipants from this cohort again. Meanwhile, we enrolled another
cohort of 403 consecutive unselected individuals diagnosed with
VTand 471 controls. In total, 1,406 Chinese individuals were diag-
nosed with VT and were registered at the Hubei Clinical and
Research Center of Thrombosis and Hemostasis between March
1, 2008 and June 30, 2012. Among the 1,406 eligible individuals
with VT, 33 died of VT or its complications before inclusion, 49
were out of contact, and 20 refused to participate because they
were in the end stage of a disease, such as malignancy. Therefore,
these 102 individuals did not participate in the case-control study.
In addition, 168 of the 1,502 eligible healthy Chinese subjects
were out of contact or refused to take part in this genetic study.
Finally, a total of 1,304 cases and 1,334 controls were available.
The sample collection and the criteria for diagnosis of VT were
previously described.22 The validation of VTwas based on the clin-
ical manifestations, a D-dimer assay, and compression ultrasound
or venography (for deep-vein thrombosis), as well as ventilation
and perfusion lung scanning, computed-tomography angiog-
raphy, or pulmonary angiography (for pulmonary thromboembo-
lism). Age- and sex-matched control participants, without an indi-
vidual or family history of thrombosis (arterial thrombosis and
VT), were enrolled from a community screening program during
the same period. The case and control groups had similar median
ages (52 years for both), 5th–95th percentile age (26–73 years versus
27–74 years), and sex distribution (49% male for both groups).
The demographic data and acquired risk factors, including age,
gender, smoking, malignancy, sedentariness or immobility, preg-
nancy or puerperium, oral contraceptives, hormone-replacement
therapy, and lupus anticoagulant, were recorded. The citrated
blood sample was separated into plasma and buffy-coat cells by
centrifugation. Genomic DNA was extracted from the buffy-coat
cells according to standard procedures. Plasma lupus anticoagu-
lant was detected by an activated-partial-thromboplastin-time
(APTT)-based functional assay with commercial reagents (Dade
Behring-Siemens Healthcare Diagnostics, Margurg, Germany) on
a Sysmex CA 7000 Analyzer (Sysmex, Kobe, Japan). The two
common polymorphisms (PROC c.565C>T [p.Arg189Trp] and
c.574_576dup/del [p.Lys192del]) associated with VT in the
Chinese population were genotyped in the study population178 The American Journal of Human Genetics 92, 177–187, Februarywith the PCR-RFLP (restriction-fragment-length polymorphism)
methods as described.21,22
We named these series of studies by evaluating the risk of throm-
bophilia or VT as MAGIC (multiple assessments of genetic risk
factors for thrombophilia in the Chinese population). All the
procedures followed in this study were approved by the ethics
committee of Union Hospital at Huazhong University of Science
and Technology in accordance with the ethical standards of
human experimentation and complied with the principles ex-
pressed in the Declaration of Helsinki. Written informed consent
was obtained from all participants.
Resequencing of THBD
The putative promoter, 50 UTR, coding region, and 30 UTR of THBD
were screened with the PCR and sequencing method in 60 cases
randomly selected from the VT individuals who were free from
antithrombin (encoded by SERPINC1 [MIM 107300]), PC, or PS
deficiency, the PROC c.565C>T (p.Arg189Trp) mutation, and the
PROC c.574_576del (p.Lys192del) variant. The identified variants
were further detected by resequencing in 60 randomly selected
controls. The primer-pair sequences used in the amplification are
summarized in Table S1, available online. The resequencing was
performed on an ABI PRISM 3730XL DNA sequencer (Applied Bio-
systems, Carlsbad, CA, USA). The RefSeq accession numbers for
THBD and protein sequences reported in this paper are
NG_012027.1, NM_000361.2, and NP_000352.1.
Genotyping
On the basis of the genetic screening, a SNP (c.151G>T) in the 50
UTR was supposed to be associated with VT and was subsequently
investigated in the study population. This variant was genotyped
with the PCR-RFLP assay (Figure S1). Primers 50-GCACTTCC
TTCCTTTTCCCGA-30 and 50-CAGAGGGGCACAGGACGC-30
were employed in the PCR reaction. The digestion was performed
by incubation of 2.5 U of Mwo I and 1 ml of 103 buffer Tango (Fer-
mentas, Burlington, ON, Canada) with 10 ml of the PCR product
for 12 hr at 37C. The digestion fragments were separated by 2%
agarose-gel electrophoresis. A total of 96 DNA samples were
randomly selected and subjected to sequencing for validation of
the genotyping results. The accuracy of the RFLP assay was 100%.
Measurement of Plasma TM Antigen
Plasma soluble thrombomodulin (sTM) was measured in 48
heterozygotes for the c.151G>T variant and in 48 age- and sex-
matched normal individuals from the case-control study with
the use of the Human Thrombomodulin-BDCA-3 Quantikine
ELISA Kit (R&D Systems, Minneapolis, MN, USA).
Family Analysis of VT Risk
Family members of 38 carriers (29 individuals with VT and 9
healthy controls from the case-control study) of the
c.151G>T variant agreed to participate in the family analysis.
Each family comprised at least two members (one c.151G>T
carrier and one noncarrier). For the avoidance of selection bias,
the analyses were confined to the first-degree relatives of the
38 index carriers. In total, 176 first-degree relatives from 38 fami-
lies were enrolled. Written inform consent was obtained, and
blood samples were collected for coagulation tests (antithrombin
amidolytic activity, PC amidolytic activity, and PS cofactor
activity) and genotyping. The medical histories and acquired
risk factors for thrombosis were also obtained. Thrombosis was7, 2013
Table 1. Variants Identified in THBD in 60 VT Individuals and 60 Controls
dbSNP ID HGVS Name Gene Region
Number of VT Cases
(Hetero/Homo)
Number of Controls
(Hetero/Homo)
rs13306848 c.202G>A promoter 8 (8/0) 7 (7/0)
rs16984852 c.151G>T 50 UTR 3 (3/0) 1 (1/0)
NA c.256C>A (p.Leu86Ile) CDS 8 (8/0) 9 (9/0)
NA c.569C>G (p.Ser190Trp) CDS 1 (1/0) 0 (0/0)
NA c.636C>A (p.Ser212*) CDS 1 (1/0) 0 (0/0)
rs1042579 c.1418C>T (p.Ala473Val) CDS 13 (9/4) 12 (8/4)
NA c.1456G>T (p.Asp486Tyr) CDS 1 (1/0) 1 (1/0)
rs13306852 c.*26C>T 30 UTR 3 (3/0) 3 (3/0)
NA c.*50A>C 30 UTR 1 (1/0) 1 (1/0)
rs3176134 c.*277G>A 30 UTR 1 (1/0) 1 (1/0)
The following abbreviations are used: HGVS, human genome variation society; hetero, heterozygous; homo, homozygous; NA, not available; and CDS, coding
sequence.also confirmed on the basis of objective techniques and docu-
mented in their medical records. For each group (affected and
unaffected family relatives), we calculated the annual incidence
of thrombosis by dividing the number of thrombotic events by
the total number of affected individuals per year. The years of
follow-up were defined as the time period between the date of
birth and either the date of the first episode of VT, if any, or
June 1, 2012. The relative risk for the c.151G>T mutation
was calculated with only the first thrombotic event during the
follow-up.Plasmid Construction, Cell Culture, Transfection, and
Luciferase Assay
Fragments of the wild-type and mutated promoter and 50 UTR,
spanning nucleotides 419 to 64 (with respect to the ATG
codon), were amplified and subcloned into the pGL3-basic vector
(Promega, Madison, WI, USA) containing the firefly luciferase
gene (Fluc). The genomic DNA of both an individual with the
c.151G>T mutation and a normal subject were used as
templates. The primers used in the plasmid constructions are
shown in Table S1. The constructs were confirmed by sequencing.
Human umbilical-vein endothelial cells (HUVECs), human
embryonic kidney (HEK) 293 cells, and COS-7 cells were obtained
from the American Type Culture Collection (Manassas, VA, USA)
or Cellbank of the Chinese Academy of Sciences (Shanghai,
China) and were cultured under the recommended conditions.
Approximately 90% confluent cells in 96-well plates were tran-
siently cotransfected with Lipofectamine 2000 (Invitrogen, Carls-
bad, CA, USA) with 300 ng of the pGL3 luciferase reporter vectors
and 10 ng of the pRL-SV40 inner control vector (Promega, Madi-
son, WI, USA), which contained the Renilla luciferase gene
(Rluc). Four types of pGL3 vector were separately transfected:
pGL3 with the normal 50 UTR (pGL3-WT), pGL3 with the mutant
50 UTR (pGL3-MT), pGL3 with an efficient SV40 promoter (pGL3-
promoter), and pGL3 lacking any promoter (pGL3-basic). The
relative luciferase activity (the ratio of F-luciferase activity to
R-luciferase activity) was determined 36 hr later with the Dual-
Luciferase Reporter Assay System (Promega,Madison,WI, USA) ac-
cording to the manufacturer’s instructions. Six independent
experiments were performed.The AmericStatistical Analysis
The statistical analyses were performed with SPSS 13.0 software
(SPSS, Chicago, IL, USA). Continuous variables were expressed as
means5 SD. The comparison between groups was performed by
an unpaired Student’s t test or Mann-Whitney U test, as appro-
priate. Categorical variables were expressed as percentages, and
the differences were analyzed by a chi-square test. A Cox regres-
sion was performed for estimating the relative risk (hazard ratio)
of thrombosis in the first-degree relatives with the TM defect.
The thrombosis-free survival was assessed with Kaplan-Meier
curves. A two-tailed p < 0.05 was considered to be statistically
significant.Results
Identification of Variants in THBD
The resequencing of THBD in 60 individuals with VT
revealed ten genetic variants, including one in the
promoter region, one in the 50 UTR, five in the coding
sequence, and three in the 30 UTR (Table 1). On the basis
of bioinformatics tools (PolyPhen-2 and miRDB),37,38
c.256C>A (p.Leu86Ile), c.1418C>T (p.Ala473Val), and
three 30 UTR variants might be benign or tolerated. No
differences in the genotype distribution of g.4959G>A
and c.1456G>T (p.Asp486Tyr) were observed between
the groups. In addition, c.569C>G (p.Ser190Trp) and
c.636C>A (p.Ser212*) were located at the hydrophobic
region between the lectin-like and EGF-1 domains and
were highly conserved. Especially, c.636C>A (p.Ser212*),
a nonsense mutation, leads to a truncated protein lacking
346 amino acids. These two variants might have delete-
rious consequences. However, neither of them was
observed in 60 healthy controls, indicating rare mutations.
Therefore, these variants were not further studied. The re-
maining variant, c.151G>T, was present in three individ-
uals with VT and only one control. This variant was in low
linkage disequilibriumwith other polymorphisms and was
thus detected in the whole study population.an Journal of Human Genetics 92, 177–187, February 7, 2013 179
Table 2. Data from the Participants Enrolled in the MAGIC Study
Variable
Cases (n ¼ 1,304) Controls (n ¼ 1,334)
p Valuen % n %
Age (years) 51.7 5 13.8 51.3 5 14.2 0.468
Sex male 638 48.9% 649 48.7% 0.887
female 666 51.1% 685 51.3%
Smoking yes 271 20.8% 240 18.0% 0.070
no 1,033 79.2% 1,094 82.0%
Malignancy yes 81 6.2% 6 0.4% 1.179 3 1016
no 1,223 93.8% 1,328 99.6%
Immobility yes 30 2.3% 15 1.2% 0.038
no 1,274 97.7% 1,319 98.8%
Pregnancy or puerperium yes 34 2.6% 18 1.3% 0.020
no 1,270 97.4% 1,316 98.7%
OCT or HRP yes 16 1.2% 7 0.5% 0.052
no 1,288 98.8% 1,327 99.5%
Lupus anticoagulant positive 65 5.0% 12 0.9% 4.61 3 1010
negative 1,239 95.0% 1,322 99.1%
Years of age are expressed as means5 SD. The age of cases is the age at the first incident, and the age of controls is the age at enrollment. Age was further divided
into three levels: under 40 years, 40–60 years, and over 60 years. Immobility and OCT reflect the 4 weeks prior to the VT incident. The following abbreviations are
used: VT, venous thrombosis; OCT, oral contraceptives; and HRT, hormone-replacement therapy.Association between the c.151G>T Variant and VT
Risk
The characteristics and demographic data of the study pop-
ulation are presented in Table 2. According to the genotyp-
ing results, the heterozygous THBD c.151G>T variant
was identified in 35 VT individuals and 13 controls. The
homozygous genotype was absent in all the participants.
Thus, carriers of the variant allele in the heterozygous state
had a 2.80-fold (95% confidence interval [CI] ¼ 1.48–5.32)
risk of developing VT (Table 3). The statistical power was
0.913, and the type-I-error probability was 0.05. In addi-
tion, with respect to the two common genetic risk factors
recently reported in the Chinese population, the PROC
c.565C>T mutation was present in 5.21% of the VT indi-
viduals and in 0.90% of the controls. Likewise, the PROC
c.574_576del polymorphism was detected in 6.52% and
2.40% of the subjects from the case and control groups,
respectively.
Association between the c.151G>T Genotype and
sTM Levels
The plasma sTM antigen was determined in 48 heterozy-
gotes (22 males and 26 females) for this variant and in
48 subjects (22 males and 26 females) with a normal
genotype. As illustrated in Figure 1, the mean values of
sTM of variant carriers were significantly lower than
those of noncarriers by sex group (in men: 6.18 5
1.59 ng/ml versus 7.36 5 1.25 ng/ml, p ¼ 0.009; in
women: 5.15 5 1.29 ng/ml versus 6.00 5 1.00 ng/ml,180 The American Journal of Human Genetics 92, 177–187, Februaryp ¼ 0.011). Likewise, in the case group, the mean
sTM level was significantly lower in THBD c.151G>T
carriers (5.74 5 1.66 ng/ml) than in noncarriers
(6.59 5 1.38, p ¼ 0.024). In the control group, the
mean sTM level was also lower in variant carriers
(5.30 5 0.98 ng/ml) than in noncarriers (6.72 5
1.14 ng/ml, p ¼ 0.002).
Thrombotic Risk in First-Degree Relatives and
Lifetime Risk of Thrombosis
Overall, 81 of the total 176 relatives were identified as
carriers of the c.151G>T variant, and one of these had
the PROC c.574_576del variant. The other 95 relatives
had a normal THBD genotype, and of these, one had the
PROC c.574_576del variant and one had PS deficiency
(PS cofactor activity: 39 U/dl). In total, 16 thrombosis
events were confirmed in these relatives. Precipitating
factors (pregnancy, puerperium, oral contraceptives,
immobility, and malignancy) for the first episodes of
thrombosis were analyzed. Thrombosis occurred sponta-
neously in seven, whereas predisposing factors were
present in the other nine. As shown in Table 4, first-degree
relatives with the c.151G>T variant had a higher inci-
dence of thrombosis than did those without this variant
(3.41/1,000 versus 0.94/1,000 persons per year), as well
as a higher relative thrombosis risk (3.42; 95% CI ¼ 1.03–
11.33). When analysis was performed for VT individuals’
relatives, first-degree relatives with the c.151G>T variant
had a higher incidence of thrombosis than did those7, 2013
Table 3. Association between the Common Genetic Risk Factors Identified and VT in the Chinese Population
Genotype
Cases Controls Risk of VT
PARn ¼ 1,304 n ¼ 1,334 OR (95% CI) p Value
PROC c.565C>T (p.Arg189Trp)
C/C 1,236 (94.79%) 1,322 (99.10%) 1 - -
C/T 68 (5.21%) 12 (0.90%) 6.06 (3.26–11.25) 1.03 3 1010 4.67%
PROC c.574_576dup/del (p.Lys192del)
dup/dup 1,219 (93.48%) 1,302 (97.60%) 1 - -
dup/del þ del/del 85 (6.52%) 32 (2.40%) 2.84 (1.88–4.29) 2.77 3 107 4.14%
THBD c.151G>T
G/G 1,269 (97.32%) 1,321 (99.03%) 1 - -
G/T 35 (2.68%) 13 (0.97%) 2.80 (1.48–5.32) 1.02 3 103 1.48%
Hardy-Weinberg equilibrium tests for PROC c.565C>T, PROC c.574_576dup/del, and THBD c.151G>T are p ¼ 0.869, 0.657, and 0.858, respectively. The
following abbreviations are used: VT, venous thrombosis; OR, odds ratio; CI, confidence interval; and PAR, population-attributable risk.without this variant (3.30/1,000 versus 0.95/1,000 persons
per year), as well as a higher relative thrombosis risk (3.38;
95% CI ¼ 1.02–11.14). Likewise, when analysis was per-
formed for controls’ relatives, the incidence of thrombosis
was also greater in the first-degree relatives with the
c.151G>T variant (3.83 per 1,000 persons per year)
than in those without this variant (0.90 per 1,000 persons
per year). Although the affected relatives had a higher rela-
tive risk (2.00; 95% CI ¼ 0.18–22.06) of thrombosis, the
analysis was not statistically significant (p ¼ 0.571), which
might be due to the limited sample size in the group of
controls’ relatives. The Kaplan-Meier analysis showed
that the probability of remaining thrombosis-free was
significantly lower (p ¼ 0.012 for analysis of the VT indi-
viduals’ relatives group; p ¼ 0.029 for analysis of the
combined relatives) in relatives with the c.151G>T
variant than in those without the variant (Figure 2). For
the total first-degree relatives, the probability of being
cumulative thrombosis-free at age 55 years was 76.6%
and 97.6% for affected and unaffected relatives,
respectively.
Consequence of the c.151G>T Variant on Gene
Expression In Vitro
For assessment of the functional relevance of the variant,
a luciferase assay was performed. In Figure 3, the gene-
expression levels of different constructs are measured as
relative light units (the ratio of F-luciferase activity to
R-luciferase activity). The pGL3-basic vector, which did
not contain any promoter elements, was used as a negative
control. Compared with the wild-type allele, the
c.151G>T variant significantly reduced the reporter
gene-expression level in all three kinds of cells (HUVECs:
0.88 5 0.14 versus 0.56 5 0.06, p ¼ 4.62 3 104; HEK
293 cells: 1.94 5 0.12 versus 1.14 5 0.08, p ¼ 9.13 3
108; and COS-7 cells: 2.56 5 0.10 versus 1.88 5 0.12,
p ¼ 9.21 3 107).The AmericRare Mutations
In order to verify that the prevalence of deleterious muta-
tions in THBD among individuals with VT was relatively
high in the Chinese population, we resequenced this locus
in another set of thrombophilic individuals. That was,
another 48 individuals enrolled in our study population
were selected for THBD analysis. The selection criterion
was based on an onset of age under 45 years accompanied
with a recurrent thrombosis history or a family thrombosis
history. Direct sequencing revealed another three variants
in two severe thrombophilic individuals. A 10-year-old
boy was found to be a compound heterozygote for the
c.376G>T (p.Asp126Tyr) mutation and the c.*6_*23del
variant (an 18deoxynucleotide deletion,whichwas 6deox-
ynucleotides downstream of the stop codon) according to
the clone-sequencing analysis. A 45-year-oldmanwas iden-
tified to be a heterozygote for the c.659T>G (p.Leu220*)
nonsense mutation. Both of the two persons suffered
fromat least three episodesof thrombosis, includingarterial
thrombosis in the lower extremity. These two persons,
together with the two previously described individuals
carrying either p.Ser190Trp or p.Ser212*, were chosen for
plasma sTM assay and familial analysis when family
members were available. Table 5 shows that all these
probands had a decreased sTM level and that mutations
p.Ser190Trp and p.Ser212* cosegregated with a reduced
sTM level in the two pedigrees. However, other members
carrying these mutations had not suffered from an arte-
rial-thrombosis or a VT event yet. With respect to the 30
UTR mutation (c.*6_*23del), it occurred at the miR-3155a
and miR-3155b target site (50-GAGCCTG-30), and it there-
fore might affect mRNA stability and cause suppression of
protein translation. Moreover, consequences of the two
nonsense mutations are probably deleterious. Therefore,
the five mutations are likely to be causative. These further
support the fact that THBD variants might be a relatively
prevalent cause of VT.an Journal of Human Genetics 92, 177–187, February 7, 2013 181
Figure 1. Association between the sTM Level and the
c.151G>T Genotype
(A) Sex-matched data. Error bars represent the SD.
(B) Data matched for case-control status. The sTM level was deter-
mined in 48 heterozygotes and 48 individuals with a normal geno-
type via the ELISA (enzyme-linked immunosorbent assay)
method. Each sample was tested in duplicate. Error bars represent
the SD.Discussion
This study investigated the relationship between possible
THBD variants and the development of VT and revealed
that the c.151G>T polymorphism (rs16984852: G>T)
causes a predisposition to VT. The case-control study
showed that the heterozygous genotype for this variant
confers an approximately 2.80-fold increased risk of VT
in the Chinese population. The family study indicated
that first-degree relatives bearing this variant have a 3.42-
fold increased risk of VT. These findings are further sup-
ported by in vitro functional luciferase assays in which
the c.151T mutant allele reduced the total expression
level to 59%–73% of the c.151G wild-type in all three
cell types.
The intronless human THBD is located in chromosomal
region 20p11.21 and is 3.6 kb in length.39 The association182 The American Journal of Human Genetics 92, 177–187, Februarybetween THBD variation and the susceptibility to VT is bio-
logically plausible because of the essential role of TM in an-
ticoagulation. However, to date, only a fewmutations have
been confirmed to be associated with arterial-thrombosis
and VT events, and these mutations were all rare and
only observed in some special cases or populations.40–43
As for THBD polymorphisms, several studies have mainly
focused on three common polymorphisms (c.202G>A,
c.127G>A [p.Ala43Thr], and c.1418C>T [p.Ala473Val]).
Sugiyama et al.44 evaluated the contribution of genetic
variations in THBD to sTM level and deep-vein thrombosis
in 118 Japanese VT individuals and controls. They indi-
cated that the mean values of sTM were lower in C-allele
carriers of c.*1001A>C (in tight linkage disequilibrium
with c.1418C>T [p.Ala473Val]) than in noncarriers
and that the CC homozygous genotype might be a
genetic risk factor for thrombosis in Japanese men.
On the contrary, studies in white populations45–48 have
not shown any association between the c.202G>A,
c.127G>A (p.Ala43Thr), and c.1418C>T (p.Ala473Val)
variants and sTM levels or an obvious susceptibility to
thrombosis, suggesting that these known polymorphisms
are not likely to be a common risk factor for VT in the
general population. In the present study, the c.202G>A
and c.1418C>T variants were observed in the Chinese
population, and the similar genotype distribution in
cases and controls also indicates that they might be no
more than an extremely weak, if at all, risk factor for
thrombosis. In addition, the c.151G>T variant, which
was strongly suggested to be associated with a decreased
level of gene expression and an increased risk of
thrombosis in this research, was not identified in those
previous studies. Therefore, thrombotic disease caused by
inherited TM deficiency has remained largely unexplored
because of the difficulty in examining the phenotype of
this endothelial transmembrane protein. Given that sTM
was present in human plasma, we tested whether the
plasma concentrations of sTM might reflect the endo-
thelial expression of thrombomodulin. The ELISA
(enzyme-linked immunosorbent assay) showed that the
mean plasma sTM level of the c.151G>T carriers was
significantly lower than that of noncarriers. Our results
are in accordance with the Atherosclerosis Risk in Commu-
nities Study, which suggested that there was a strong,
graded, and inverse relation association between sTM
concentration and coronary heart disease.49 Therefore,
plasma concentrations of sTM might reflect endothelial
expression of thrombomodulin to some degree. However,
the sample size of the sTM-antigen test was rather small
as a result of the relatively low penetration of this variant.
Therefore, this observation should be validated by a larger
study.
With the development of access to healthcare and epide-
miological studies, an increase in the annual incidence of
VT has been observed in the past decade, and the incidence
of VT in Asian populations has been estimated to be 50–
115 per 100,000 individuals per year.50–53 The difference7, 2013
Table 4. Family Analysis of Thrombotic Risk in c.151G>T Carriers and Noncarriers
Parameters
VT Persons’ Relatives Controls’ Relatives Total Relatives
Carriers Noncarriers Carriers Noncarriers Carriers Noncarriers
Total number of first-degree relatives 63 72 18 23 81 95
Median age (range) in years 46 (12–66) 43 (18–66) 45 (16–69) 46 (34–71) 46 (12–69) 43 (18–71)
Male/female 35/28 41/31 10/8 16/7 45/36 57/38
Number of VT events 9 3 3 1 12 4
Median age at first thrombosis in years 46 37 51 62 50 46
Years of follow-upa 2,731 3,144 784 1,106 3,515 4,250
Events per 1,000 persons per year 3.30 0.95 3.83 0.90 3.41 0.94
Relative risk for thrombosis (95% CI)b 3.38 (1.02–11.14) 1 2.00 (0.18–22.06) 1 3.42 (1.03–11.33) 1
The annual incidence of thrombosis was calculated by a division of the number of thrombotic events by the total number of affected individuals per year. The
following abbreviations are used: VT, venous thrombosis; and CI, confidence interval.
aThe years of follow-up are defined as the time period between the date of birth and either the date of the first episode of VT, if any, or June 1, 2012, and are the
total combined number of years of follow-up for all individuals.
bData were analyzed with a Cox regression, and the relative risk for the c.151G>T mutation was calculated with only the first thrombotic event during the
follow-up.in the incidence between Asian andWestern populations is
smaller than previously reported, and VT is believed to be
a common disease in Asians. However, the prevalence of
VT is, in fact, still lower in Asians than in whites. The
ethnic variation in VT should be attributed to the
genetic-background disparity among ethnicities. At
present, we have identified three common genetic risk
factors (PROC c.565C>T, PROC c.574_576dup/del, and
THBD c.151G>T) in the Chinese population; their
respective prevalences are approximately 0.90%, 2.40%,
and 0.98%, and their estimated population-attributable
risk is 4.67%, 4.14%, and 1.48%, respectively (Table 3).
These variants conferred a 6.06-, 2.84-, and 2.80-fold
increased risk, respectively, of developing VT. TakenFigure 2. Thrombosis-free Survival in Relatives
(A) Analysis was performed for VT persons’ relatives.
(B) Analysis was performed for the total relatives. The probability of
Kaplan-Meier analysis. The green plot shows relatives with the c.1
mutation.
The Americtogether, these mild to moderate thrombophilic risk
factors account for ~10% of the total VT events in the
general population. It is worth noting that the prevalence
of these polymorphisms is much lower than that of the
most common genetic risk factor in whites, the factor V
Leiden (5%–10%),24 which is associated with an approxi-
mately 5-fold higher risk of VT. This difference might
partially explain the relatively lower incidence of throm-
bosis in Asians compared to whites.
Apart from the genetic-risk-factor findings, this study
might have other important inspirations. First, we have
hitherto identified three common variants in the throm-
bosis-pathway genes. Therefore, resequencing of the hemo-
stasis genesmightbeuseful forunravelingunknowngeneticthrombosis-free survival in first-degree relatives was estimated by
51G>T mutation, and the blue plot shows relatives without the
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Figure 3. Gene-Expression Levels Deter-
mined by the Luciferase Assay
(A) Schematic of reporter gene constructs.
Known regulatory elements (SP1 sites,
CAAT box, and TATA box) in the promoter
of THBD are schematically represented.
(B) Luciferase activity. Transfection and
luciferase assay were performed in three
kinds of cells (HUVECs, HEK 293 cells,
and COS-7 cells). The pGL3-basic vector
was used as a negative control. The lucif-
erase activities are expressed as the ratio
of firefly to Renilla luciferase units. The
values represent means 5 SD of six inde-
pendent experiments. The black column
represents the wild-type construct, and
the gray column represents the mutant
construct. Error bars represent the SD.defects for thrombophilia and VT in future research, which
isparticularlyhelpful forAfricans because thesepopulations
are reported to have the highest incidence of VT among all
ethnicities; however, few common genetic risk factors
have been identified in Africans so far.36 Second, the minor
allele frequencies (MAFs) of the three variants are all rela-
tively low (prevalences between 0.90% and ~2.40%,
MAF < 5%) but could confer high risk (odds ratio [OR] > 2)
of VT. This is quite different from most previous genetic
studies, such as genome-wide association studies54–56 in
which the identified variants often had a higher frequency
(MAF > 5% or 10%) but a lower risk (OR < 1.5). Hence,
low-frequency polymorphisms might play a more impor-
tant role in thedevelopment ofVTandother complexdisor-
ders, and it might therefore be important to include low-
penetrance SNPs (MAF < 5%) in future disease-association
studies. Third, in addition to the common c.151G>T
variant, five other rare mutations (c.376G>T, c.569C>G,
c.636C>A, c.659T>G, and c.*6_*23del) in THBD were also
identified by sequencing in 108 individuals with VT. These
mutations, especially the nonsense variants, might also be
causative. This proportion (5/108) was relatively high. As
a result, one might expect that more mutations in THBD
would be identified in the entire VT group and that an in-
herited TM defect would be more common in Chinese VT
individuals. We should pay more attention to THBDmuta-
tions in thrombosis-affected persons. Further systematic184 The American Journal of Human Genetics 92, 177–187, February 7, 2013research on the genetics of TM defects
is thus warranted. Finally, investi-
gating the link between the THBD
c.151G>T variant and arterioscle-
rotic vascular disorders, such as coro-
nary artery disease, might be valuable
because it has been well established
that VT and atherothrombosis share
some similar physiopathological
processes57,58 and that there is a strong
association between TM defect and
atherosclerosis.59,60In conclusion, this study is the largest on the genetic
background of VT in the Chinese population. We reported
that the common THBD c.151G>T variant is associated
with both impaired 50 UTR function and an increased
risk of VT. In combination with the two PROC variants,
these three common genetic risk factors could account
for approximately 1/10 of the VT events in the general
population. The prevalence and relative risk of VT of these
variants in other populations (especially in Asians) will
require further evaluation.Supplemental Data
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